Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

PET-CT Based Radiotherapy in Esophageal Cancer Patients

This study has been completed.
Information provided by (Responsible Party):
Maastricht Radiation Oncology Identifier:
First received: July 2, 2010
Last updated: December 5, 2014
Last verified: December 2014
The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients.

Esophageal Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Consequences of Positron-Emission-Tomography/Computed Tomography (PET/CT) Based Radiotherapy Treatment Planning for Clinical Outcome in Esophageal Cancer Patients

Resource links provided by NLM:

Further study details as provided by Maastricht Radiation Oncology:

Primary Outcome Measures:
  • Locoregional control [ Time Frame: 2 years and 5 years ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 2 years and 5 years ]
  • Disease Free survival [ Time Frame: 2 years and 5 years ]
  • Tumor regression grade [ Time Frame: At the time of surgery ]
    Tumor regression grade at time of surgery evaluated by pathologist.

Enrollment: 115
Study Start Date: November 2007
Study Completion Date: May 2013
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Detailed Description:
The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary Care Clinic

Inclusion Criteria:

  • Histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus
  • Local curable disease able to undergo Chemoradiotherapy.

Exclusion Criteria:

  • Metastasized disease.
  • Previous or concurrent malignancies.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01156831

Atrium Hospital
Heerlen, Netherlands
University Medical Center
Maastricht, Netherlands
St. Laurentius Hospital
Roermond, Netherlands
Maasland Hospital
Sittard, Netherlands
St. Jansgasthuis
Weert, Netherlands
Sponsors and Collaborators
Maastricht Radiation Oncology
Principal Investigator: Guido Lammering, MD PhD Radiation Oncology, Maastro Clinic
Principal Investigator: Meindert Sosef, MD PhD Atrium Hospital Heerlen
  More Information

Responsible Party: Maastricht Radiation Oncology Identifier: NCT01156831     History of Changes
Other Study ID Numbers: 09-18-12/08
Study First Received: July 2, 2010
Last Updated: December 5, 2014

Keywords provided by Maastricht Radiation Oncology:
Esophageal cancer
PET-CT planning

Additional relevant MeSH terms:
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases processed this record on May 25, 2017